|1.||Schally, Andrew V: 14 articles (06/2013 - 08/2002)|
|2.||Block, Norman L: 6 articles (06/2013 - 11/2010)|
|3.||Rick, Ferenc G: 6 articles (06/2013 - 10/2009)|
|4.||Schally, A V: 6 articles (05/2013 - 05/2000)|
|5.||Diedrich, Klaus: 5 articles (10/2009 - 01/2002)|
|6.||Emons, Günter: 5 articles (07/2004 - 02/2002)|
|7.||Szalontay, Luca: 4 articles (06/2013 - 10/2009)|
|8.||Halmos, Gabor: 4 articles (04/2012 - 09/2007)|
|9.||Gründker, Carsten: 4 articles (07/2004 - 02/2002)|
|10.||Diedrich, K: 4 articles (06/2003 - 04/2000)|
05/01/1992 - "Histological parameters also demonstrated significant tumor inhibition, with the best results being obtained by treatment with the antagonist SB-75. "
05/01/1992 - "In mice which received microgranules liberating 50 micrograms/day of antagonist SB-75, there was a greater decrease in tumor weight and volume than that produced by the agonist and a significant reduction in the weight of the testes and accessory sex organs. "
08/01/2002 - "The protein levels of p21 (a Cdk inhibitor) and p53 (a suppressor of tumor cell growth and a positive regulator for p21 expression) were increased by Cetrorelix, but the levels of p27 (a Cdk inhibitor) did not change significantly. "
08/01/1997 - "In another TG mouse line (IT6-F), with more aggressive tumorigenesis, the SB-75 treatment only partially inhibited gonadal tumor growth. "
08/01/1997 - "Gonadal tumor growth was clearly inhibited by SB-75 treatment in one of the TG mouse lines (IT6-M), as indicated by the absence of macroscopically visible tumors and by reduced gonadal weights. "
|2.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
10/01/2010 - "To compare the efficacy of 4 dosage regimens of cetrorelix pamoate, a sustained release formulation that allows for more convenient dosing, in patients with symptomatic benign prostatic hyperplasia (BPH). "
06/01/2012 - "In the present study, we investigated the roles of TGF-β signaling pathway in a rat benign prostatic hyperplasia (BPH) model treated with cetrorelix. "
10/01/2005 - "Cetrorelix is mainly used for in vitro fertilization protocols, but research is currently being carried out in benign prostatic hypertrophy. "
01/01/1994 - "In this trial, we evaluated the response to 500 micrograms SB-75 given every 12 hr subcutaneously (sc) for 4 weeks in 11 patients with benign prostatic hyperplasia (BPH), and 6 weeks in 6 prostatic cancer patients (2 stage C, 4 stage D2). "
10/01/2010 - "Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia."
|3.||Leiomyoma (Uterine Fibroids)
10/01/2007 - "To assess the efficacy and safety of different dosing schedules of cetrorelix acetate as a short term treatment for 4 weeks prior to surgery in patients with uterine fibroids. "
10/01/2007 - "Presurgical short term treatment of uterine fibroids with different doses of cetrorelix acetate: a double-blind, placebo-controlled multicenter study."
11/01/2005 - "Effect of cetrorelix acetate on apoptosis and apoptosis regulatory factors in cultured uterine leiomyoma cells."
02/01/2005 - "The number of viable cultured leiomyoma cells was significantly (P < 0.01) decreased by treatment with Cetrorelix compared with untreated control cultures. "
09/01/1997 - "Overall results support the use of Cetrorelix for the management of uterine leiomyomas."
|4.||Prostatic Neoplasms (Prostate Cancer)
07/01/2006 - "Major oncological studies were also carried out with agonist D-Trp6-LH-RH and antagonist Cetrorelix in men with prostate cancer, which demonstrated therapeutic efficacy of both types of analogs. "
01/01/1998 - "Clinical studies with cetrorelix in prostate cancer; in vitro fertilization, and benign prostate hypotrophy have been reported."
01/31/2005 - "The ability of Cetrorelix to downregulate EGFR signalling and subsequently reverse the antiadhesiveness found in metastatic prostate cancer highlights a novel potential target for therapeutic strategies."
10/16/1998 - "To investigate the mechanisms involved, we treated male nude mice bearing xenografts of DU-145 human androgen-independent prostate cancer with Cetrorelix at a dose of 100 microg/animal subcutaneously (s.c.) once a day. "
02/01/1991 - "The results indicate that antagonist SB-75, released from sustained delivery systems, can produce a state of chemical castration and effectively inhibit the growth of experimental prostate cancers. "
10/01/2006 - "Cetrorelix in the treatment of female infertility and endometriosis."
10/01/2006 - "Cetrorelix also seems to be useful in the treatment of endometriosis which, in most cases, is an estrogen-dependent disease. "
12/01/2008 - "In the present study, we aimed to compare the effects of cetrorelix and leuprolide on endometriosis. "
01/08/2010 - "Cetrorelix is used for IVF-ET procedures and for the treatment of benign prostatic hyperplasia, endometriosis and leiomyomas. "
04/06/2004 - "The results suggest that Cetrorelix in low doses induces only a partial pituitary-gonadal inhibition and might be indicated for treatment of endometriosis, leiomyomas, and benign prostatic hyperplasia."
|1.||Gonadotropin-Releasing Hormone (GnRH)
|2.||LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)
|4.||Messenger RNA (mRNA)
|6.||Epidermal Growth Factor (EGF)
|10.||Insulin-Like Growth Factor I (IGF-1)
|3.||Drug Therapy (Chemotherapy)
|5.||Heterologous Transplantation (Xenotransplantation)